Información de la publicación

Portal del Investigador > Publicaciones > detalle publicacion

Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in patients with newly diagnosed multiple myeloma (NDMM) not eligible or with no immediate intent for transplant: long-term efficacy and safety in a phase 1b study

Otras comunicaciones del congreso o articulos relacionados con autores/as de la Universidad de Cantabria

Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development - Artículo de Revista
Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome - Artículo de Revista
Randomized phase 2 study of weekly carfilzomib 70 Mg/m2 and dexamethasone plus/minus cyclophosphamide in relapsed and/or refractory multiple myeloma (RRMM) patients (GEM-KyCyDex) - Artículo de Revista
Hnrnpk overexpression drives nucleolar aberrancies causing ribosomopathies - Comunicación a Congreso
Genetic subtyping using whole exome sequencing across large B cell lymphoma entities in a series of 109 DLBCL and plasmablastic lymphoma cases - Comunicación a Congreso
Results from the cohort-expansion stage of a phase I trial of tinostamustine monotherapy in advanced Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL) and multiple myeloma (MM) (NCT02576496) - Comunicación a Congreso
30-minute infusion of isatuximab in newly diagnosed multiple myeloma (NDMM) patients: results of a phase 1b study - Comunicación a Congreso
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients - Artículo de Revista
The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis - Artículo de Revista
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma - Artículo de Revista
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile - Artículo de Revista
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma - Artículo de Revista
ETV6-RUNX1 promotes survival of early B lineage progenitor cells via a dysregulated erythropoietin receptor - Artículo de Revista
Comparative effectiveness of linvoseltamab versus current real-world (RW) standard-of-care (SOC) therapies in triple-class exposed relapsed/refractory multiple myeloma (RRMM): key subgroups analysis - Comunicación a Congreso
A first in human study of VOB560 in combination with MIK665 in patients with relapsed/refractory non-hodgkin lymphoma, acute myeloid leukemia, or multiple myeloma - Comunicación a Congreso
Mezigdomide (MEZI) in novel-novel combinations for relapsed or refractory multiple myeloma (RRMM): preliminary results from the CA057-003 trial - Comunicación a Congreso
Zanubrutinib is effective in the treatment of patients with Waldenström's Macroglobulinemia and Bing-Neel Syndrome: a retrospective multicenter study - Comunicación a Congreso
Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies - Artículo de Revista
Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations - Artículo de Revista
Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia - Artículo de Revista
Natural history and cell of origin of TC F3- ZN F384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL - Artículo de Revista
Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs - Artículo de Revista
PLCG1 mutations in cutaneous T-cell lymphomas - Artículo de Revista

Editorial: American Society of Hematology

Año de publicación: 2024

Nº de páginas: 3

Tipo de publicación: Comunicación a Congreso

DOI: 10.1182/blood-2024-200135

ISSN: 0006-4971,1528-0020

Url de la publicación: https://doi.org/10.1182/blood-2024-200135

Leer publicación

Autoría

ENRIQUE MARIA OCIO SAN MIGUEL

PERROT, AURORE

BORIES, PIERRE

SAN-MIGUEL, JESÚS F.

KARLIN, LIONEL

MARTÍNEZ-LÓPEZ, JOAQUÍN

WANG, SONG-YAU

BRINGHEN, SARA

MATEOS, MARÍA-VICTORIA

RODRÍGUEZ-OTERO, PAULA

OLIVA, STEFANIA

NOGAI, AXEL

PAIVA, BRUNO

LI, YI

LE BRAS, ERIC

MACÉ, SANDRINE

KODAS, ERCEM

VAN DE VELDE, HELGI

MOREAU, PHILIPPE

Descargar referencia

Bib Ris

Volver

Researchers portal

Portal del personal investigador

Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in patients with newly diagnosed multiple myeloma (NDMM) not eligible or with no immediate intent for transplant: long-term efficacy and safety in a phase 1b study

Autoría

Descargar referencia